balcinrenone/dapagliflozin

巴昔利酮/达格列净

Report date: 2026/03/04 20:01:44

Base Information

Drug Namebalcinrenone/dapagliflozin
Drug Alias NameAZD9977/dapagliflozin
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMineralocorticoid receptor modulatorsSodium/glucose cotransporter 2 inhibitors
TargetsMineralocorticoid receptorSodium/glucose cotransporter 2
Therapy Area/IndicationsHeart FailureCardiovascular DiseasesProteinuria +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[39] 
CombinationsYes BalcinrenoneDapagliflozin Propanediol Monohydrate
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Ab
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PlcAstrazeneca AbAstraZeneca global R & D (China) Co Ltd
Inactive CompaniesN/A
Active IndicationsHeart FailureProteinuriaRenal Insufficiency, Chronic +[4] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A